Our research strategy
At Cure Parkinson’s we have a single goal: to identify curative therapies for Parkinson’s. This narrow remit helps to keep our attention focused.
Our research strategy has been developed with help from individuals within the research and the Parkinson’s patient community. It has been a collaborative process that has provided us with a clear roadmap for the next few years.
As part of this, we have identified four key objectives:
- Grow our treatment selection programme – the International Linked Clinical Trials (iLCT) initiative developed in partnership with Van Andel Institute.
- Accelerate the clinical testing of new therapies – with the development of novel clinical trial platforms for Parkinson’s.
- Champion the development of combination therapies – seeking to maximise any synergistic effects to generate a greater impact in slowing Parkinson’s.
- Make disease modification more personalised – targeting particular agents towards specific types of Parkinson’s.
These objectives build-on the work we have done so far and will help drive us closer to the identification of disease-modifying therapies for Parkinson’s.
Our clear focus means we are relentless in our pursuit of these objectives and the ultimate goal of disease modification for Parkinson’s. We will bring together those who share this ambition and work collaboratively with them as we all strive for a world without Parkinson’s.
Dr Simon Stott, Director of Research, Cure Parkinson’s
